Mary Wilson
Well-known member
Published: February 07, 2022
Publication History
Accepted: February 2, 2022
Received in revised form: January 16, 2022
Received: December 14, 2021
DOI: https://doi.org/10.1016/j.chom.2022.02.003
Esther Dawen Yu, Eric Wang, Emily Garrigan, Benjamin Goodwin, Aaron Sutherland, Alison Tarke, James Chang, Rosa Isela Gálvez, Jose Mateus, Sydney I. Ramirez, Stephen A. Rawlings, Davey M. Smith, Gilberto Filaci, April Frazier, Daniela Weiskopf, Jennifer M. Dan, Shane Crotty, Alba Grifoni, Alessandro Sette, Ricardo da Silva Antunes
Highlights
A T cell-based assay allows discrimination of SARS-CoV-2 infection and vaccination
The classification scheme has high sensitivity, specificity and broad applicability
The use of SARS-CoV-2 epitope pools yield higher accuracy than serological readouts
Breakthrough infections can be effectively segregated from vaccine responses
SUMMARY
Both SARS-CoV-2 infection and COVID-19 vaccines elicit memory T cell responses. Here, we report the development of two pools of experimentally-defined SARS-CoV-2 T cell epitopes, that in combination with spike, were used to discriminate four groups of subjects with different SARS-CoV-2 infection and COVID-19 vaccine status. The overall T cell-based classification accuracy was 89.2% and 88.5% in the experimental and validation cohorts. This scheme was applicable to different mRNA vaccines, different lengths of time post-infection/post-vaccination, and yielded increased accuracy when compared to serological readouts. T cell responses from breakthrough infections were also studied, and effectively segregated from vaccine responses, with a combined performance of 86.6% across all 239 subjects from the five groups. We anticipate that a T cell-based immunodiagnostic scheme to classify subjects based on their vaccination and natural infection history will be an important tool for longitudinal monitoring of vaccination and establishing SARS-CoV-2 correlates of protection.
https://www.cell.com/cell-host-micro...cleInformation
PDF: https://www.cell.com/action/showPdf?...2822%2900089-0
Publication History
Accepted: February 2, 2022
Received in revised form: January 16, 2022
Received: December 14, 2021
DOI: https://doi.org/10.1016/j.chom.2022.02.003
Esther Dawen Yu, Eric Wang, Emily Garrigan, Benjamin Goodwin, Aaron Sutherland, Alison Tarke, James Chang, Rosa Isela Gálvez, Jose Mateus, Sydney I. Ramirez, Stephen A. Rawlings, Davey M. Smith, Gilberto Filaci, April Frazier, Daniela Weiskopf, Jennifer M. Dan, Shane Crotty, Alba Grifoni, Alessandro Sette, Ricardo da Silva Antunes
Highlights
A T cell-based assay allows discrimination of SARS-CoV-2 infection and vaccination
The classification scheme has high sensitivity, specificity and broad applicability
The use of SARS-CoV-2 epitope pools yield higher accuracy than serological readouts
Breakthrough infections can be effectively segregated from vaccine responses
SUMMARY
Both SARS-CoV-2 infection and COVID-19 vaccines elicit memory T cell responses. Here, we report the development of two pools of experimentally-defined SARS-CoV-2 T cell epitopes, that in combination with spike, were used to discriminate four groups of subjects with different SARS-CoV-2 infection and COVID-19 vaccine status. The overall T cell-based classification accuracy was 89.2% and 88.5% in the experimental and validation cohorts. This scheme was applicable to different mRNA vaccines, different lengths of time post-infection/post-vaccination, and yielded increased accuracy when compared to serological readouts. T cell responses from breakthrough infections were also studied, and effectively segregated from vaccine responses, with a combined performance of 86.6% across all 239 subjects from the five groups. We anticipate that a T cell-based immunodiagnostic scheme to classify subjects based on their vaccination and natural infection history will be an important tool for longitudinal monitoring of vaccination and establishing SARS-CoV-2 correlates of protection.
https://www.cell.com/cell-host-micro...cleInformation
PDF: https://www.cell.com/action/showPdf?...2822%2900089-0
